Global Healthcare M&A Monthly Report - January 2026

In January 2026, there were a total of 33 M&A transactions in the global healthcare sector, with the publicly disclosed total transaction value amounting to approximately $2.717 billion (about 19.397 billion RMB). The domestic market saw 2 M&A events, with the total transaction value undisclosed; the overseas market witnessed 31 M&A events, with the disclosed total transaction value at approximately $2.717 billion.

In terms of M&A in细分 fields of the global medical and health industry, the digital health sector was the most active in M&A transactions this month, with 13 M&A events, accounting for 39.39% of the entire field; the biopharmaceutical sector had the highest total transaction value, approximately $1.24 billion, accounting for 45.63% of the entire field.

This month's highlighted projects include: Amgen's $840 million acquisition of precision oncology drug developer Dark Blue Therapeutics; Smith+Nephew's $450 million acquisition of soft tissue repair solutions developer Integrity Orthopaedics; Illumina's $425 million plus specified royalties acquisition of data-driven proteomics technology leader SomaLogic; Halozyme Therapeutics' $400 million acquisition of preclinical biopharmaceutical company Surf Bio and its subcutaneous injection platform; Sword Health's $285 million acquisition of digital therapeutics developer Kaia Health; Haemonetics' €185 million acquisition of vascular closure device developer Vivasure Medical; OpenAI's $60 million acquisition of AI healthcare application developer Torch Health; and BioMerieux's €35 million all-cash acquisition of biotechnology service platform provider Accellix.